Adult T-cell leukemia/lymphoma
MONDO:0019471A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1), adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.
Also known as: ATLL, T-cell leukaemia of adults, T-cell leukemia of adults, adult T-cell leukaemia, adult T-cell leukemia, adult T-cell leukemia/lymphoma, HTLV-1 associated adult T-cell lymphoma/leukemia, HTLV-I associated adult T-cell leukemia/lymphoma
1969 clinical trials for this condition and its sub-types, 31 tagged with Adult T-cell leukemia/lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New combo shows promise against Tough-to-Treat lymphoma
Disease control CompletedThis study tested a combination of the targeted drug brentuximab vedotin (ADCETRIS) plus standard CHP chemotherapy in 82 people with newly diagnosed peripheral T-cell lymphoma (PTCL) that has low CD30 levels. The goal was to see how many patients' tumors shrank or disappeared. Re…
Phase 2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a targeted antibody boost chemotherapy against a rare leukemia?
Disease control CompletedThis study tests whether adding a targeted drug called brentuximab vedotin to standard chemotherapy can help people with adult T-cell leukemia/lymphoma (ATLL), a rare and aggressive blood cancer. The combination, known as BV-CHEP, aims to improve response rates by targeting a mar…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug combo aims to control rare blood cancer
Disease control CompletedThis phase 2 trial tested a combination of belinostat (a cancer drug) and zidovudine (AZT, an HIV drug) as consolidation therapy for adult T-cell leukemia-lymphoma (ATLL), a rare and aggressive blood cancer. Fifteen participants received the drugs to see if it could eliminate can…
Phase 2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New cocktail targets tough lymphomas
Disease control CompletedThis early-phase study tested a combination of three drugs (VIP152, venetoclax, and prednisone) in 8 adults with aggressive non-Hodgkin lymphomas that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose, while also measuri…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Experimental drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis study tested a drug called brentuximab vedotin in 23 people with a type of T-cell lymphoma that had stopped responding to or returned after prior chemotherapy. The drug is designed to seek out and kill cancer cells that have a specific marker called CD30, even when levels of…
Phase 2 • Sponsor: Deepa Jagadeesh • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC